基本信息
views: 4
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Graduated in biology, I started to work in the Neuroimmunology and NeuroInflammation group, under the supervision of Dra. Laura Leyva and Dra. Begoña Oliver at the Regional University Hospital in Málaga (Biomedical Research Institute of Malaga (IBIMA)). First, I worked as a collaborator studying drug targets and mesenchymal stem cell therapy in a mouse model of experimental autoimmune. The work in that project helped me to gain an extensive knowledge of the state-of-the-art techniques in neuroimmunology, cell therapy and mouse models. As results in that stage, I published scientific articles in high impact journals as a collaborator (PMID: 22591409; PMID: 25498031; PMID: 27882538). During these years, I completed the Neurosciences and Clinical Applications PhD program at the University of Malaga. I acquired the doctor's degree in 2017 with the highest qualification “cum laudem” with a thesis focused on the search of biomarkers for monitoring the treatment responses in Multiple Sclerosis patients. My major achievements: 1) I found an activation pattern of the IFNβ pathway in monocytes from MS patients that is associated with the clinical phenotype of good response to IFNβ treatment and that a differential modulation of the IFNAR subunits in monocytes could be related with treatment effectiveness (Hurtado-Guerrero I. et al. PLoS One. 2017). 2) I showed that cross-reactivity of neutralizing antibodies against IFNβ (NAbs) increases with the titter of antibodies, which has important implications in clinical practice when switching the treatment. The direct relationship between the NAbs titter and the activation of STAT1 suggest that its determination could be an indirect method to identify the presence of NAbs (Hurtado-Guerrero I. et al. Sci Rep. 2017). 3) I found a gene signature associated with IFNβ responder patients, carried out by gene expression microarray at 4, 12 and 24h after administration of IFNβ to responder or non-responder MS patients, (publication pending). In parallel to my thesis, I collaborated in other projects funded in public competitive calls, as a study on the epigenetic of MS (PMID: 28821874; PMID: 32722577) and especially in the study of the soluble interferon-β receptor 2 (IFNAR2) as biomarker in MS and the intrinsic activities of a recombinant soluble IFNAR2 (PMID: 26571364; PMID: 27452720; PMID: 27613121) in which, after my PhD, I was the postdoc in charge of the experimental approaches of this project.
My motivation to reveal the basic functions of this biomarker led me to apply successfully to the iNEXT Project, funding by the Horizon 2020 EU Programme. Accordingly, I contacted the Neuroinflammation Unit head by Prof. Issazadeh-Navikas from the University of Copenhagen in Denmark, a research leader in the forefront of IFNβ functions. Issazadeh-Navikas´s lab has established an international reputation in the field of immune regulatory function of neurons and how neurons communicate with local and circulating immune cells. I wrote and successfully received both, an EMBO Short-Term Fellowship and a Research Training Stay Fellowship from Junta de Andalucía, for a 6 months stay to deepen in the mechanism of action of the soluble IFNAR2 and to learn new techniques in the basic area of neurobiology at Issazadeh-Navikas´s lab in 2019. As a result, some outcomes obtained during this stay were published in my first author paper (Hurtado-Guerrero I. et al. J Clin Med. 2020). Notably, I obtained a Marie Skłodowska-Curie Individual Fellowships-2019 funding by the Horizon 2020 Programme. As a result, I joined the Issazadeh-Navikas´s lab with my current postdoc position at the University of Copenhagen. My current project focuses on to reveal the potential actions of soluble IFNAR2, as IFNβ-signalling regulator, and as a novel signalling molecule with intrinsic activities in maintaining the neuronal homeostasis of Parkinson. Up until now, I have found that Parkinsonism patients (PD and Multiple System Atrophy) present significantly lower serum levels of sIFNAR2 than controls, indicating dysregulation in this pathway. Further, I have established for the first time that recombinant human sIFNAR2 induces an increase in mitochondrial membrane potential and mitochondrial mass in a neural cell line, this fact is very significant since classically a decrease in mitochondrial membrane potential in neurons is associated with PD (publications pending). During my stay at the University of Copenhagen I have supervised a Degree Final Project (TFG) and currently a Master's Thesis.
Research Interests
Papers共 22 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nicolás Lundahl Ciano-Petersen, Pablo Aliaga-Gaspar,Isaac Hurtado-Guerrero,Virginia Reyes,José Luis Rodriguez-Bada, Eva Rodriguez-Traver, Isabel Brichette-Mieg,Laura Leyva Fernández,Pedro Serrano-Castro,Ana Alonso,Begoña Oliver-Martos
Frontiers in Immunology (2023): 1242508
Cited0Views0Bibtex
0
0
A. Alonso-Torres,M. J. Pinto-Medel,I. Hurtado-Guerrero,J. Ortega-Pinazo,J. L. Rodriguez-Bada, P. Urbaneja-Romero,B. Oliver-Martos,L. Leyva
Cited0Views0Bibtex
0
0
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn